A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic

► The maximum tolerated dose and feasibility of IV docetaxel, IP carboplatin and IP paclitaxel were assessed. ► First cycle RPII Dose did not predict toxicity over multiple cycles.